Streamlining the Product Portfolio Through the Transfer of Long-Listed Products
First written in FY2019-Q2. 2 of 3 entries say "Advanced", first in FY2019-Q3. Latest entry: FY2026.
4 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「The co-promotion agreement with AstraZeneca plc (United Kingdom) for dapagliflozin ended in March 2026.」
The co-promotion agreement with AstraZeneca for Forxiga ended, and the difference of ¥4.3 billion between the consideration for the transfer of the marketing rights and their carrying amount was recorded as a loss on the transfer of intangible assets. - FY2019-Q3AdvancedAnnual report
「Royalties and other income increased by ¥18.8 billion, or 46.2%, year on year to ¥59.4 billion, owing mainly to higher royalty income from Opdivo intravenous infusion from Bristol-Myers Squibb and recognition of income associated with the transfer of 5 brands and 11 injectable long-listed products to Marunishi Pharmaceutical Co., Ltd.」
Income associated with the transfer of 5 brands and 11 long-listed injectable products to Marunishi Pharmaceutical was recorded in royalties and other income for the nine months ended the third quarter following the signing of the transfer agreement. - FY2019-Q2First statedAnnual report
「Company: Marunishi Pharmaceutical; Japan; transfer of marketing approvals for 5 brands and 11 injectable long-listed products; upfront payment; September 2018」
In September 2018, a transfer agreement was signed with Marunishi Pharmaceutical Co., Ltd. for the marketing approvals of 5 brands and 11 injectable long-listed products, giving concrete form to the streamlining of the product portfolio.